Fate Therapeutics Presents Preclinical Efficacy Data for WNT7A-Analog Program at Muscular Dystrophy Association 2013 Scientific Conference
4/22/2013 1:28:56 PM
More...
|
Fate Therapeutics Strengthens Leadership Position in the Development of Wnt-based Protein Therapeutics
12/4/2012 9:40:48 AM
More...
|
Fate Therapeutics Initiates Phase 2 Clinical Study of ProHema for the Treatment of Hematologic Malignancies
11/27/2012 8:51:32 AM
More...
|
Fate Therapeutics Names Christian Weyer New CEO
10/15/2012 7:26:34 AM
More...
|
Fate Therapeutics Raises $9.2 Million for Stem Cell Treatments
8/23/2012 8:27:51 AM
More...
|
Fate Therapeutics And BD Biosciences (BDX) Launch BD(TM) SMC4 to Improve Cellular Reprogramming and IPS Cell Culture Applications
6/11/2012 12:01:48 PM
More...
|
Fate Therapeutics Announces the Appointment of William H. Rastetter as Chairman of its Board of Directors and Interim CEO
12/14/2011 7:48:10 AM
More...
|
Fate Therapeutics Announces Promising Data From Phase 1b Study of ProHema at the 2011 American Society of Hematology Annual Conference
12/13/2011 10:50:37 AM
More...
|
Fate Therapeutics Secures Foundational Patent for iPS Cell Reprogramming
12/9/2011 10:15:18 AM
More...
|
Fate Therapeutics Strengthens Its iPSC Platform
11/16/2011 11:16:08 AM
More...
|
|